You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethotrimeprazine
Accession NumberDB01403
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Structure
Thumb
Synonyms
(-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine
2-Methoxytrimeprazine
Levomepromazina
Levomepromazine
Levomepromazinum
Methotrimeprazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethoprazineTablet5 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet25 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet50 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet2 mgOralAa Pharma Inc1998-07-20Not applicableCanada
Methotrimeprazine-2Tablet2 mgOralPro Doc Limitee1999-05-102009-07-23Canada
Methotrimeprazine-25Tablet25 mgOralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-5Tablet5 mgOralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-50Tablet50 mgOralPro Doc Limitee1999-05-102011-07-27Canada
Nov Meprazine Tab 50mgTablet50 mgOralNovopharm Limited1996-12-312005-08-10Canada
Novo Meprazine Tab 25mgTablet25 mgOralNovopharm Limited1996-12-31Not applicableCanada
Novo Meprazine Tab 5mgTablet5 mgOralNovopharm Limited1995-07-17Not applicableCanada
Nozinan 5mg TabTablet5 mgOralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
Nozinan 5mg/mlSolution5 mgOralSanofi Aventis Canada Inc1966-12-312006-07-28Canada
Nozinan Inj 25mg/mlSolution25 mgIntramuscular; IntravenousSanofi Aventis Canada Inc1958-12-31Not applicableCanada
Nozinan Liq 40mg/mlLiquid; Solution / drops40 mgOralAventis Pharma Inc1963-12-312005-08-01Canada
Nozinan Tab 25mgTablet25 mgOralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
Nozinan Tab 2mgTablet2 mgOralAventis Pharma Inc1958-12-312005-08-01Canada
Nozinan Tab 50mgTablet50 mgOralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
PMS-methotrimeprazineTablet25 mgOralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazineTablet50 mgOralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazineTablet5 mgOralPharmascience Inc1997-10-20Not applicableCanada
Riva-meprazine 25mg TabletsTablet25 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 50mg TabletsTablet50 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 5mg TabletsTablet5 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LevopromeNot Available
NeurocilNot Available
NosinanNot Available
NozinanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9G0LAW7ATQ
CAS number60-99-1
WeightAverage: 328.472
Monoisotopic: 328.16093409
Chemical FormulaC19H24N2OS
InChI KeyVRQVVMDWGGWHTJ-CQSZACIVSA-N
InChI
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
IUPAC Name
[(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine
SMILES
COC1=CC2=C(SC3=C(C=CC=C3)N2C[[email protected]](C)CN(C)C)C=C1
Pharmacology
IndicationFor the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
Structured Indications
PharmacodynamicsMethotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Mechanism of actionMethotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(1B) dopamine receptorProteinunknown
antagonist
HumanP21918 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Related Articles
AbsorptionMethotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.

Route of eliminationNot Available
Half lifeApproximately 20 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include convulsions, spastic movements, and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
2,5-Dimethoxy-4-ethylamphetamineMethotrimeprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMethotrimeprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methotrimeprazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Methotrimeprazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
AbirateroneThe serum concentration of Methotrimeprazine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
AcebutololMethotrimeprazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Methotrimeprazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methotrimeprazine.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Methotrimeprazine.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methotrimeprazine.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Methotrimeprazine.Approved
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Methotrimeprazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Methotrimeprazine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Amantadine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
AmiodaroneMethotrimeprazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
AmodiaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Methotrimeprazine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Methotrimeprazine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Methotrimeprazine.Approved
AnagrelideMethotrimeprazine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.Approved
Aop200704Methotrimeprazine may increase the hypotensive activities of Aop200704.Investigational
ApomorphineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Methotrimeprazine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Methotrimeprazine.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ArotinololMethotrimeprazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMethotrimeprazine may increase the QTc-prolonging activities of Artemether.Approved
ArtemisininThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Methotrimeprazine can be increased when it is combined with Artesunate.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
AtenololMethotrimeprazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.Approved
AtovaquoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Atovaquone.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
AzelastineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinMethotrimeprazine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methotrimeprazine.Investigational
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit
BedaquilineMethotrimeprazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololMethotrimeprazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Methotrimeprazine.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BenzphetamineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Methotrimeprazine.Approved
Betulinic AcidThe serum concentration of Methotrimeprazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololMethotrimeprazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideMethotrimeprazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Methotrimeprazine.Approved
BopindololMethotrimeprazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
BromocriptineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
BucindololMethotrimeprazine may increase the hypotensive activities of Bucindolol.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methotrimeprazine.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Methotrimeprazine.Experimental, Investigational
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
BupranololMethotrimeprazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Methotrimeprazine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methotrimeprazine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Methotrimeprazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Methotrimeprazine.Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Methotrimeprazine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Methotrimeprazine.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methotrimeprazine.Experimental
CelecoxibThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMethotrimeprazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
CeritinibMethotrimeprazine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Methotrimeprazine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ChlorphentermineMethotrimeprazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CholecalciferolThe metabolism of Methotrimeprazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methotrimeprazine.Experimental
CilostazolThe metabolism of Cilostazol can be decreased when combined with Methotrimeprazine.Approved
CimetidineThe metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Methotrimeprazine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Methotrimeprazine.Approved
CiprofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMethotrimeprazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMethotrimeprazine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ClotrimazoleThe metabolism of Methotrimeprazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CobicistatThe serum concentration of Methotrimeprazine can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
CrizotinibMethotrimeprazine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.Approved, Investigational
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Methotrimeprazine.Approved, Investigational
DarunavirThe serum concentration of Methotrimeprazine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Methotrimeprazine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Methotrimeprazine.Approved
DelavirdineThe metabolism of Methotrimeprazine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methotrimeprazine.Investigational
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Methotrimeprazine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Methotrimeprazine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Methotrimeprazine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Methotrimeprazine.Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Vet Approved
DiethylpropionMethotrimeprazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DihydroartemisininThe serum concentration of Methotrimeprazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methotrimeprazine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Methotrimeprazine.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DisopyramideMethotrimeprazine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideMethotrimeprazine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Methotrimeprazine.Approved
DomperidoneMethotrimeprazine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Methotrimeprazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Methotrimeprazine.Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methotrimeprazine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Methotrimeprazine.Approved, Investigational
DoxycyclineThe serum concentration of Methotrimeprazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DronedaroneMethotrimeprazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methotrimeprazine.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Methotrimeprazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Methotrimeprazine.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Methotrimeprazine.Investigational
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Methotrimeprazine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Methotrimeprazine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
ErythromycinMethotrimeprazine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramMethotrimeprazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Methotrimeprazine.Investigational
EsmololMethotrimeprazine may increase the hypotensive activities of Esmolol.Approved
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.Approved, Investigational
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Methotrimeprazine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FluoxetineMethotrimeprazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Methotrimeprazine.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Methotrimeprazine.Approved, Investigational
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Methotrimeprazine.Approved, Investigational
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Gadobenic acidMethotrimeprazine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
GemifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methotrimeprazine.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methotrimeprazine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.Approved
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methotrimeprazine.Approved
GoserelinMethotrimeprazine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Methotrimeprazine.Approved, Investigational
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methotrimeprazine.Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Methotrimeprazine.Approved
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
HydrocodoneMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
Hydroxyamphetamine hydrobromideMethotrimeprazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.Approved
IbutilideMethotrimeprazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Methotrimeprazine.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Methotrimeprazine.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.Investigational, Withdrawn
IndenololMethotrimeprazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Methotrimeprazine can be decreased when combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methotrimeprazine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methotrimeprazine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methotrimeprazine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methotrimeprazine.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methotrimeprazine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methotrimeprazine.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
IsoniazidThe metabolism of Methotrimeprazine can be decreased when combined with Isoniazid.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Methotrimeprazine.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
KetoconazoleThe metabolism of Methotrimeprazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Methotrimeprazine.Approved
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LenvatinibMethotrimeprazine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideMethotrimeprazine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LevobunololMethotrimeprazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Methotrimeprazine.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Methotrimeprazine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methotrimeprazine.Approved
LisdexamfetamineMethotrimeprazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Methotrimeprazine.Approved
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Methotrimeprazine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Methotrimeprazine.Approved
LopinavirMethotrimeprazine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Methotrimeprazine.Approved
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
LumefantrineMethotrimeprazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
MefloquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mefloquine.Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MephedroneMethotrimeprazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Methotrimeprazine.Investigational, Withdrawn
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Methotrimeprazine.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Methotrimeprazine.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Methotrimeprazine.Approved, Illicit, Withdrawn
MetipranololMethotrimeprazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MetyrosineMethotrimeprazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Methotrimeprazine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Methotrimeprazine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methotrimeprazine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methotrimeprazine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Methotrimeprazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Methotrimeprazine.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MizoribineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mizoribine.Investigational
MMDAMethotrimeprazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Methotrimeprazine.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MoxifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
NadololMethotrimeprazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Methotrimeprazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Methotrimeprazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
NetupitantThe metabolism of Netupitant can be decreased when combined with Methotrimeprazine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Methotrimeprazine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Methotrimeprazine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Methotrimeprazine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Methotrimeprazine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.Approved
NilotinibMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OfloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
OrphenadrineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Methotrimeprazine.Approved, Investigational
PanobinostatThe serum concentration of Methotrimeprazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Methotrimeprazine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.Approved
Peginterferon alfa-2bThe serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMethotrimeprazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Methotrimeprazine.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
PerflutrenMethotrimeprazine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Methotrimeprazine.Approved
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Methotrimeprazine.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PhentermineMethotrimeprazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Methotrimeprazine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Methotrimeprazine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PiribedilThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Piribedil.Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.Approved
PractololMethotrimeprazine may increase the hypotensive activities of Practolol.Approved
PramipexoleMethotrimeprazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PrimaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ProcainamideMethotrimeprazine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methotrimeprazine.Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
ProguanilThe serum concentration of Methotrimeprazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Methotrimeprazine.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Methotrimeprazine.Approved, Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Methotrimeprazine.Approved
PyrimethamineThe serum concentration of Methotrimeprazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Methotrimeprazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
QuinacrineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Methotrimeprazine.Approved
QuinidineMethotrimeprazine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMethotrimeprazine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
RadicicolThe serum concentration of Methotrimeprazine can be increased when it is combined with Radicicol.Experimental
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Methotrimeprazine.Approved
RanolazineThe metabolism of Methotrimeprazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Methotrimeprazine.Investigational
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
RitobegronMethotrimeprazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Methotrimeprazine.Approved
RolapitantThe metabolism of Methotrimeprazine can be decreased when combined with Rolapitant.Approved
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
RopiniroleMethotrimeprazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
RotigotineMethotrimeprazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methotrimeprazine.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Methotrimeprazine.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methotrimeprazine.Approved
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methotrimeprazine.Approved, Investigational, Vet Approved
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Methotrimeprazine.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Methotrimeprazine.Approved
SinefunginThe serum concentration of Methotrimeprazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
SotalolMethotrimeprazine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Methotrimeprazine.Experimental
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
SulfadoxineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleMethotrimeprazine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Methotrimeprazine.Approved, Investigational
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
tafenoquineThe serum concentration of Methotrimeprazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methotrimeprazine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.Approved, Investigational
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Methotrimeprazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Methotrimeprazine.Investigational, Withdrawn
TelavancinMethotrimeprazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMethotrimeprazine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TerbinafineThe metabolism of Methotrimeprazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Methotrimeprazine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Methotrimeprazine.Investigational
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
ThalidomideMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Methotrimeprazine.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Methotrimeprazine.Investigational
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methotrimeprazine.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Methotrimeprazine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Methotrimeprazine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Methotrimeprazine.Approved
TipranavirThe metabolism of Methotrimeprazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
TolterodineThe metabolism of Tolterodine can be decreased when combined with Methotrimeprazine.Approved, Investigational
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ToremifeneMethotrimeprazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Methotrimeprazine.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Methotrimeprazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methotrimeprazine.Withdrawn
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Methotrimeprazine.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
VandetanibMethotrimeprazine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibMethotrimeprazine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Methotrimeprazine.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Methotrimeprazine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Methotrimeprazine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Methotrimeprazine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Methotrimeprazine.Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methotrimeprazine.Approved, Investigational
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation.
References
Synthesis Reference

Christian Berger, “Process for preparing levomepromazine hydrogen maleate.” U.S. Patent US4798895, issued January 17, 1989.

US4798895
General References
  1. Link [Link]
External Links
ATC CodesN05AA02
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.9935
Caco-2 permeable+0.6694
P-glycoprotein substrateSubstrate0.6805
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8571
Renal organic cation transporterNon-inhibitor0.5132
CYP450 2C9 substrateNon-substrate0.7511
CYP450 2D6 substrateSubstrate0.5363
CYP450 3A4 substrateSubstrate0.6056
CYP450 1A2 substrateInhibitor0.6953
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5432
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5633
Ames testNon AMES toxic0.5562
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.932
hERG inhibition (predictor II)Inhibitor0.8488
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral2 mg
TabletOral25 mg
TabletOral5 mg
SolutionOral5 mg
SolutionIntramuscular; Intravenous25 mg
Liquid; solution / dropsOral40 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Nozinan 25 mg/ml3.6USD ml
Apo-Methoprazine 50 mg Tablet0.4USD tablet
Apo-Methoprazine 25 mg Tablet0.27USD tablet
Apo-Methoprazine 5 mg Tablet0.1USD tablet
Apo-Methoprazine 2 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility20 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.68HANSCH,C ET AL. (1995)
logS-4.22ADME Research, USCD
pKa9.19SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00525 mg/mLALOGPS
logP4.84ALOGPS
logP4.25ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.83 m3·mol-1ChemAxon
Polarizability36.77 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-056r-9356000000-bb17e4980980d336d337View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Comments
comments powered by Disqus
Drug created on July 10, 2007 12:38 / Updated on August 17, 2016 12:23